EXAS insider transaction filings
EXACT SCIENCES CORP — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-23. Screen EXAS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-23 | 4 | Baranick Brian — EVP, GM, Precision Oncology | Grant/award (A): 33,321 @ $0 · Disposition to issuer (D): 137,195 · Disposition to issuer (D): 795 · Disposition to issuer (D): 28,063 (derivative) | EDGAR |
| 2026-03-23 | 4 | Herriott James — SVP, General Counsel & Sec | Disposition to issuer (D): 68,195 · Disposition to issuer (D): 1,762 · Disposition to issuer (D): 793 (derivative) · Disposition to issuer (D): 2,861 (derivative) · Disposition to issuer (D): 20,321 (derivative) | EDGAR |
| 2026-03-23 | 4 | Bloomer Aaron — EVP, Chief Financial Officer | Grant/award (A): 89,911 @ $0 · Disposition to issuer (D): 138,679 · Disposition to issuer (D): 417 · Disposition to issuer (D): 4,395 (derivative) · Disposition to issuer (D): 28,063 (derivative) | EDGAR |
| 2026-03-23 | 4 | Condella Sarah — EVP, Human Resources | Grant/award (A): 60,389 @ $0 · Disposition to issuer (D): 191,891 · Disposition to issuer (D): 6,368 · Disposition to issuer (D): 21,948 (derivative) · Disposition to issuer (D): 11,700 (derivative) · Disposition to issuer (D): 7,790 (derivative) · +2 more | EDGAR |
| 2026-03-23 | 4 | Conroy Kevin T — President and CEO, Director | Grant/award (A): 119,312 @ $0 · Disposition to issuer (D): 1,397,738 · Disposition to issuer (D): 29,061 · Disposition to issuer (D): 46,538 · Disposition to issuer (D): 86,750 · Disposition to issuer (D): 117,427 · +8 more | EDGAR |
| 2026-03-23 | 4 | ORVILLE JACOB A — EVP, GM, Screening | Grant/award (A): 53,323 @ $0 · Disposition to issuer (D): 153,726 · Disposition to issuer (D): 1,774 · Disposition to issuer (D): 6,581 (derivative) · Disposition to issuer (D): 38,707 (derivative) | EDGAR |
| 2026-03-23 | 4 | COWARD D SCOTT — Director | Disposition to issuer (D): 52,164 · Disposition to issuer (D): 5,398 · Disposition to issuer (D): 4,694 · Disposition to issuer (D): 4,175 (derivative) · Disposition to issuer (D): 10,786 (derivative) · Disposition to issuer (D): 12,875 (derivative) | EDGAR |
| 2026-03-23 | 4 | Petrovic Shacey — Director | Disposition to issuer (D): 16,406 · Disposition to issuer (D): 5,398 · Disposition to issuer (D): 7,095 | EDGAR |
| 2026-03-23 | 4 | Zanotti Katherine S — Director | Disposition to issuer (D): 55,361 · Disposition to issuer (D): 5,398 | EDGAR |
| 2026-03-23 | 4 | Popovits Kimberly J — Director | Disposition to issuer (D): 6,725 · Disposition to issuer (D): 9,656 | EDGAR |
| 2026-03-23 | 4 | Doyle James Edward — Director | Disposition to issuer (D): 52,564 · Disposition to issuer (D): 5,398 | EDGAR |
| 2026-03-23 | 4 | Clancy Paul J — Director | Disposition to issuer (D): 20,640 · Disposition to issuer (D): 5,398 | EDGAR |
| 2026-03-23 | 4 | Barber Michael J — Director | Disposition to issuer (D): 7,738 · Disposition to issuer (D): 5,398 · Disposition to issuer (D): 7,422 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Trigg Leslie — Director | Disposition to issuer (D): 3,244 · Disposition to issuer (D): 13,925 | EDGAR |
| 2026-03-03 | 4 | Conroy Kevin T — President and CEO, Director | Option exercise (M): 18,143 @ $0 · Tax withholding (F): 8,528 @ $103.25 · Option exercise (M): 22,168 @ $0 · Tax withholding (F): 10,419 @ $103.25 · Option exercise (M): 27,786 @ $0 · Tax withholding (F): 13,060 @ $103.25 · +3 more | EDGAR |
| 2026-03-03 | 4 | Condella Sarah — EVP, Human Resources | Option exercise (M): 3,900 @ $5.03 · Tax withholding (F): 1,913 @ $103.38 · Option exercise (M): 3,900 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | ORVILLE JACOB A — EVP, GM, Screening | Grant/award (A): 38,707 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Baranick Brian — EVP, GM, Precision Oncology | Grant/award (A): 28,063 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Bloomer Aaron — EVP, Chief Financial Officer | Grant/award (A): 28,063 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Condella Sarah — EVP, Human Resources | Grant/award (A): 23,224 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Herriott James — SVP, General Counsel & Sec | Grant/award (A): 20,321 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Conroy Kevin T — President and CEO, Director | Grant/award (A): 13,181 @ $0 · Tax withholding (F): 6,196 @ $103.45 · Grant/award (A): 154,829 (derivative) @ $0 | EDGAR |
| 2025-12-30 | 4 | ORVILLE JACOB A — EVP, GM, Screening | Option exercise (M): 3,955 @ $0 · Tax withholding (F): 1,859 @ $101.82 · Option exercise (M): 9,450 @ $0 · Tax withholding (F): 4,442 @ $101.82 · Option exercise (M): 14,845 @ $0 · Tax withholding (F): 6,978 @ $101.82 · +15 more | EDGAR |
| 2025-12-30 | 4 | Baranick Brian — EVP, GM, Precision Oncology | Option exercise (M): 3,955 @ $0 · Tax withholding (F): 2,009 @ $101.82 · Option exercise (M): 9,450 @ $0 · Tax withholding (F): 4,799 @ $101.82 · Option exercise (M): 14,845 @ $0 · Tax withholding (F): 7,539 @ $101.82 · +15 more | EDGAR |
| 2025-12-30 | 4 | Condella Sarah — EVP, Human Resources | Option exercise (M): 3,955 @ $0 · Tax withholding (F): 1,859 @ $101.82 · Option exercise (M): 7,560 @ $0 · Tax withholding (F): 3,554 @ $101.82 · Option exercise (M): 11,876 @ $0 · Tax withholding (F): 5,582 @ $101.82 · +10 more | EDGAR |
| 2025-12-30 | 4 | Conroy Kevin T — President and CEO, Director | Grant/award (A): 244,931 @ $0 · Tax withholding (F): 115,118 @ $101.82 · Grant/award (A): 138,326 @ $0 · Tax withholding (F): 65,014 @ $101.82 · Grant/award (A): 330,674 @ $0 · Tax withholding (F): 155,417 @ $101.82 | EDGAR |
| 2025-12-30 | 4 | Herriott James — SVP, General Counsel & Sec | Option exercise (M): 1,648 @ $0 · Tax withholding (F): 775 @ $101.82 · Option exercise (M): 3,780 @ $0 · Tax withholding (F): 1,777 @ $101.82 · Option exercise (M): 7,125 @ $0 · Tax withholding (F): 3,349 @ $101.82 · +17 more | EDGAR |
| 2025-12-30 | 4 | Bloomer Aaron — EVP, Chief Financial Officer | Option exercise (M): 38,715 @ $0 · Tax withholding (F): 17,151 @ $101.82 · Option exercise (M): 24,384 @ $0 · Tax withholding (F): 10,803 @ $101.82 · Option exercise (M): 38,715 (derivative) @ $0 · Option exercise (M): 24,384 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | ORVILLE JACOB A — EVP, GM, Screening | Sale (S): 5,000 @ $75 | EDGAR |
| 2025-11-21 | 4 | Herriott James — SVP, General Counsel & Sec | Sale (S): 1,000 @ $70 | EDGAR |
| 2025-11-06 | 4 | Herriott James — SVP, General Counsel & Sec | Sale (S): 1,500 @ $70.08 | EDGAR |
| 2025-11-06 | 4 | Baranick Brian — EVP, GM, Precision Oncology | Sale (S): 2,858 @ $70.08 | EDGAR |
| 2025-10-27 | 4 | Zanotti Katherine S — Director | Sale (S): 12,000 @ $65 | EDGAR |
| 2025-10-10 | 4 | Herriott James — SVP, General Counsel & Sec | Sale (S): 1,500 @ $60 | EDGAR |
| 2025-10-10 | 4 | Doyle James Edward — Director | Sale (S): 2,000 @ $60 | EDGAR |
| 2025-08-14 | 4 | Doyle James Edward — Director | Sale (S): 1,485 @ $42.02 | EDGAR |
| 2025-08-07 | 4 | ORVILLE JACOB A — EVP, GM, Screening | Option exercise (M): 5,350 @ $0 · Tax withholding (F): 2,515 @ $46.83 · Option exercise (M): 5,350 (derivative) @ $0 | EDGAR |
| 2025-08-07 | 4 | Baranick Brian — EVP, GM, Precision Oncology | Option exercise (M): 5,350 @ $0 · Tax withholding (F): 2,717 @ $46.83 · Option exercise (M): 5,350 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Popovits Kimberly J — Director | Grant/award (A): 9,994 @ $0 | EDGAR |
| 2025-06-16 | 4 | Doyle James Edward — Director | Grant/award (A): 5,398 @ $0 | EDGAR |
| 2025-06-16 | 4 | Barber Michael J — Director | Grant/award (A): 7,197 @ $0 | EDGAR |
| 2025-06-16 | 4 | Clancy Paul J — Director | Grant/award (A): 5,398 @ $0 | EDGAR |
| 2025-06-16 | 4 | Trigg Leslie — Director | Grant/award (A): 7,670 @ $0 | EDGAR |
| 2025-06-16 | 4 | Petrovic Shacey — Director | Grant/award (A): 5,398 @ $0 | EDGAR |
| 2025-06-16 | 4 | Zanotti Katherine S — Director | Grant/award (A): 5,398 @ $0 · Sale (S): 3,207 @ $53.20 | EDGAR |
| 2025-06-16 | 4 | LEVANGIE DANIEL J — Director | Grant/award (A): 5,398 @ $0 | EDGAR |
| 2025-06-16 | 4 | COWARD D SCOTT — Director | Grant/award (A): 5,398 @ $0 | EDGAR |
| 2025-05-08 | 4 | Herriott James — SVP, General Counsel & Sec | Grant/award (A): 363 @ $38.26 · Grant/award (A): 7,334 (derivative) @ $0 | EDGAR |
| 2025-05-01 | 4 | Trigg Leslie — Director | Grant/award (A): 8,527 @ $0 | EDGAR |
| 2025-04-17 | 4 | Bloomer Aaron — EVP, Chief Financial Officer | Option exercise (M): 11,556 @ $0 · Tax withholding (F): 5,120 @ $44.25 · Option exercise (M): 12,904 @ $0 · Tax withholding (F): 5,717 @ $44.25 · Option exercise (M): 11,566 (derivative) @ $0 · Option exercise (M): 12,904 (derivative) @ $0 | EDGAR |
Recent 8-K events — EXACT SCIENCES CORP
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-03-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-02-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-02-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EXAS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →